Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-28
DOI
10.1007/s00259-019-04584-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
- (2019) Madhav Prasad Yadav et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Lu177‐ PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution
- (2019) Rhiannon McBean et al. Journal of Medical Imaging and Radiation Oncology
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- PSMA Theranostics: Current Status and Future Directions
- (2018) Kambiz Rahbar et al. Molecular Imaging
- Results of a prospective phase 2 pilot trial of Lu177 PSMA 617 therapy for metastatic castrate resistant prostate cancer including Imaging predictors of treatment response and patterns of progression.
- (2018) Louise Emmett et al. Clinical Genitourinary Cancer
- Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
- (2018) Bernhard Grubmüller et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
- (2017) Kambiz Rahbar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival
- (2017) K. Rahbar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
- (2017) Axel Bräuer et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Repeated177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq
- (2017) Hendrik Rathke et al. JOURNAL OF NUCLEAR MEDICINE
- Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
- (2016) Kambiz Rahbar et al. CLINICAL NUCLEAR MEDICINE
- 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment
- (2016) Madhav Prasad Yadav et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177 Lu-PSMA-617
- (2016) Justin Ferdinandus et al. JOURNAL OF NUCLEAR MEDICINE
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
- (2016) R. P. Baum et al. JOURNAL OF NUCLEAR MEDICINE
- Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
- (2016) Wolfgang P. Fendler et al. Oncotarget
- Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
- (2016) Hojjat Ahmadzadehfar et al. Oncotarget
- Global Cancer Incidence and Mortality Rates and Trends--An Update
- (2015) L. A. Torre et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
- (2014) Christian M. Zechmann et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
- (2013) S. T. Tagawa et al. CLINICAL CANCER RESEARCH
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More